ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
71,314.86
-0.19%
S&P 500
5,308.13
0.09%
Dow Jones
39,806.77
-0.49%
US Dollar vs Yen
156.449
0.05%
Brent Oil
83.035
-0.59%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Avenue Therapeutics Inc (ATXI)

  7. Avenue Therapeutics Inc (ATXI) ニュース

ATXI

Avenue Therapeutics (ATXI)

Avenue Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:ATXI
日付受信時刻ニュースソース見出しコード企業名
2024/05/1621 : 30GlobeNewswire Inc.Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)NASDAQ:ATXIAvenue Therapeutics Inc
2024/05/1522 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
2024/05/1521 : 30GlobeNewswire Inc.Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:ATXIAvenue Therapeutics Inc
2024/05/1313 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATXIAvenue Therapeutics Inc
2024/05/1105 : 53Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ATXIAvenue Therapeutics Inc
2024/05/1105 : 52Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATXIAvenue Therapeutics Inc
2024/04/2921 : 00GlobeNewswire Inc.Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross ProceedsNASDAQ:ATXIAvenue Therapeutics Inc
2024/04/2420 : 30GlobeNewswire Inc.Avenue Therapeutics Announces Reverse Stock SplitNASDAQ:ATXIAvenue Therapeutics Inc
2024/03/2521 : 30GlobeNewswire Inc.Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024NASDAQ:ATXIAvenue Therapeutics Inc
2024/03/1905 : 05GlobeNewswire Inc.Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:ATXIAvenue Therapeutics Inc
2024/03/1521 : 15GlobeNewswire Inc.Avenue Therapeutics Receives Positive Listing Determination from NasdaqNASDAQ:ATXIAvenue Therapeutics Inc
2024/03/1121 : 00GlobeNewswire Inc.Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual MeetingNASDAQ:ATXIAvenue Therapeutics Inc
2024/03/0906 : 31Edgar (US Regulatory)Form PRE 14C - Other preliminary information statementsNASDAQ:ATXIAvenue Therapeutics Inc
2024/03/0906 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
2024/02/2222 : 30GlobeNewswire Inc.Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence EpilepsyNASDAQ:ATXIAvenue Therapeutics Inc
2024/02/0214 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATXIAvenue Therapeutics Inc
2024/01/2922 : 00Edgar (US Regulatory)Form DEF 14C - Other definitive information statementsNASDAQ:ATXIAvenue Therapeutics Inc
2024/01/2506 : 11Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ATXIAvenue Therapeutics Inc
2024/01/1807 : 05Edgar (US Regulatory)Form PRE 14C - Other preliminary information statementsNASDAQ:ATXIAvenue Therapeutics Inc
2024/01/1220 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
2024/01/1122 : 00GlobeNewswire Inc.Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor ConferenceNASDAQ:ATXIAvenue Therapeutics Inc
2024/01/0907 : 28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
2024/01/0523 : 15GlobeNewswire Inc.Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in ProceedsNASDAQ:ATXIAvenue Therapeutics Inc
2024/01/0422 : 30GlobeNewswire Inc.Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV TramadolNASDAQ:ATXIAvenue Therapeutics Inc
2024/01/0222 : 30GlobeNewswire Inc.Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)NASDAQ:ATXIAvenue Therapeutics Inc
2023/12/1406 : 03Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ATXIAvenue Therapeutics Inc
2023/12/1406 : 02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXIAvenue Therapeutics Inc
2023/12/0122 : 30GlobeNewswire Inc.Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual MeetingNASDAQ:ATXIAvenue Therapeutics Inc
2023/11/2906 : 05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ATXIAvenue Therapeutics Inc
2023/11/2906 : 01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ATXIAvenue Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ATXI

最近閲覧した銘柄

CCOM
US100
US Tech 100
NASDAQ
TSLA
Tesla
USI
USTECH100
US Tech 100
AMEX
XLF
Financial Select Sector
AMEX
SPY
SPDR S&P 500
NYSE
AXP
American Express
NASDAQ
GOOGL
Alphabet
COIN
ETHUSD
Ethereum
FX
USDGBP
US Dollar vs Sterling
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
VZ
Verizon Communications
CCOM
US500
US 500
USOTC
ADDYY
Adidas (QX)
NYSE
DIS
Walt Disney
NASDAQ
NVDA
NVIDIA
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有